Exciting times for the company as we sit down with Mo to discuss a record-breaking FY24, the game-changing acquisition of two clinical research units from CRS, and the strategic vision driving future growth. Mo shares insights on the synergies behind the CRS deal, the growing order book, and the evolving £40m pipeline of opportunities. Plus, we explore what’s next for the company’s M&A strategy. Don’t miss this deep dive into a company on the rise!”
